Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

11066	Companies
242787	Keywords
171016	Articles
130711	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/16/2024 at 15:00, 1 year 9 months ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences extends Research Funding Agreement with UVA to develop systemic DNase program targeting NETs to improve cancer therapy outcomes

Xenetic Biosciences DNase Program Cancer Therapy Immunotherapy NETs
BRIEF

published on 12/05/2024 at 14:50, 1 year 9 months ago

Xenetic Biosciences s'associe à PeriNess pour les services d'essais cliniques

Essais Cliniques Oncologie Biosciences Xénétiques ADNase I PeriNess Ltée.
BRIEF

published on 12/05/2024 at 14:50, 1 year 9 months ago

Xenetic Biosciences Partners with PeriNess for Clinical Trial Services

Xenetic Biosciences Clinical Trials Oncology DNase I PeriNess Ltd.
PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 9 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 10 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 10 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 10 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 10 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 10 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 10 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells

Accesswire

Published on 09/24/2026 at 08:00, 58 minutes ago

Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 09/23/2026 at 22:00, 10 hours 58 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 14 hours 33 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 17 hours 16 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 18 hours 27 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 08:45, 13 minutes ago

Huawei Unveils Six Global Power Showcases, Unlocking a New Power System with AI-Energy Synergy
Published on 09/24/2026 at 08:30, 28 minutes ago

Restoration - Quantum Data Energy PLC
Published on 09/24/2026 at 08:30, 28 minutes ago

cyan AG publishes half year report 2026 – Growth trajectory and strategic expansion continued
Published on 09/24/2026 at 08:20, 38 minutes ago

Pantum Technology Showcases New Printing Solutions at IFA 2026, Expanding European Market Strategy
Published on 09/24/2026 at 08:00, 58 minutes ago

Policy Address by Hong Kong SAR’s Chief Executive John Lee: Deepening Reforms and Leveraging Strengths for a Brighter Future

Les Echos

Published on 09/24/2026 at 08:00, 58 minutes ago

Neoen launches construction of 3 solar farms and a wind farm in France, with a total capacity of 101 MW
Published on 09/24/2026 at 08:00, 58 minutes ago

Neoen lance la construction de trois parcs solaires et un parc éolien en France pour une capacité totale de 101 MW
Published on 09/24/2026 at 07:30, 1 hour 28 minutes ago

Gimv rondt met succes private plaatsing van een obligatie af voor een bedrag van EUR 150 miljoen
Published on 09/24/2026 at 07:30, 1 hour 28 minutes ago

Gimv successfully completes private placement of a bond for an amount of EUR 150 million
Published on 09/24/2026 at 07:30, 1 hour 28 minutes ago

Gimv successfully completes private placement of a bond for an amount of EUR 150 million

View all LES ECHOS COMFI WIRE